期刊
APMIS
卷 121, 期 3, 页码 189-196出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0463.2012.02955.x
关键词
Small cell lung carcinoma; time-resolved fluorescence immunoassays; uPAR; cleaved uPAR; prognosis
资金
- Danish Research School in Molecular Cancer Research (MCRS)
- EU [201279]
Almasi CE, Drivsholm L, Pappot H, Hoyer-Hansen G, Christensen IJ. The liberated domain I of urokinase plasminogen activator receptor - a new tumour marker in small cell lung cancer. APMIS 2013; 121: 189-96. The prognosis of small cell lung cancer (SCLC) remains poor with a 5-year survival rate of 46%. In non-small cell lung cancer (NSCLC), high levels of intact and cleaved forms of the receptor for urokinase plasminogen activator (uPAR) are significantly associated with short overall survival. Our aim was therefore to determine the prognostic value of the different uPAR forms in blood from SCLC patients. Serum samples from 92 treatment naive SCLC patients were analysed. Intact uPAR, uPAR(IIII), intact and cleaved uPAR, uPAR(IIII)+uPAR(IIIII) and the liberated domain I, uPAR(I) were measured using time-resolved fluorescence immunoassays (TR-FIA 13). Assessment of association of the uPAR forms to overall survival (OS) was done using Cox regression analysis adjusted for clinical covariates [age, gender, stage, lactate dehydrogenase (LDH), WHO performance status (PS)]. Multivariate survival analysis demonstrated that high levels of uPAR(I) were significantly (p=0.009) associated with short overall survival (OS). Patients with uPAR(I) levels above the second tertile had a hazard ratio (HR) of 1.9 (95% confidence interval (CI): 1.13.3), compared to patients with levels below the first tertile. High serum uPAR(I) levels are associated with short OS in SCLC patient, independent of LDH and PS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据